This inherent predisposition of BRAFV600E CRC cells to rely on inflammatory pathways to alleviate and withstand drug pressure is underscored by our finding that the SRC-relayed PGE2 signaling cascade causes therapeutic resistance (Fig. 7f). Here, SRC is linked to colorectal carcinoma.